Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
- Registration Number
- NCT01364415
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study designed to determine the Maximum Tolerated Dose (MTD) for patients with advanced Neuroendocrine Tumors (NETs) and to characterize the safety, tolerability, Pharmacokinetics and preliminary efficacy of pasireotide LAR administered i.m. once every 28 days.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 29
- ≥18 yrs old, histologically confirmed advanced well or moderately differentiated neuroendocrine tumor/carcinoma
- unresectable metastatic NET tumor with measurable disease
- life expectancy ≥ 12 weeks
- Patients with CNS metastases who are neurologically unstable or requiring increasing doses of steroids to control their CNS disease
- patients with known hypersensitivity to somatostatin analogs
- patients with symptomatic cholelithiasis in the past 2 months
- patients with history of another known primary malignancy with exception of non-melanoma skin cancer or carcinoma in situ of uterine cervix
- patients with known history of hepatitis C or chronic active hepatitis B
- patients with diagnosis of HIV.
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Pasireotide LAR Pasireotide LAR -
- Primary Outcome Measures
Name Time Method Determine the MTD/RP2D of pasireotide LAR when administered i.m. q28 days to patients with advanced NETs Sequentiona 56 day cohorts until the MTD is determined Frequency of dose-limiting toxicities (DLTs) at each dose level associated with q28 days administration of pasireotide LAR during the first 2 treatment cycles.
- Secondary Outcome Measures
Name Time Method assess the pharmacodynamics (PD) of pasireotide LAR minimum of twelve 28 day cycles to approximately eighteen 28 day cycles Changes from baseline values in IGF-1, chromogranin A and neuron-specific enolase
assess the preliminary efficacy (anti-tumor activity) of pasireotide LAR. minimum of twelve 28 day cycles to approximately eighteen 28 day cycles Disease control rate (CR+PR+SD as assessed by RECIST 1.0). Also measure progression free survival (PFS).
assess the safety and tolerability of pasireotide LAR minimum of twelve 28 day cycles to approximately eighteen 28 day cycles Incidence of adverse drug events, overall and by severity and incidence of serious adverse events and laboratory abnormalities. Also, changes in laboratory assessments, electrocardiograms, Holter monitor, imaging for gallstones, and assessment of physical examinations such as vital signs
assess the pharmacokinetics (PK) of pasireotide LAR minimum of twelve 28 day cycles to approximately eighteen 28 day cycles Pasireotide Cmax and Ctrough
Trial Locations
- Locations (4)
H. Lee Moffitt Cancer Center & Research Institute SC-1
🇺🇸Tampa, Florida, United States
Dana Farber Cancer Institute SC-6
🇺🇸Boston, Massachusetts, United States
Cedars Sinai Medical Center Cedars Sinai 4
🇺🇸Los Angeles, California, United States
University of Texas/MD Anderson Cancer Center UT MD Anderson Cancer Ctr
🇺🇸Houston, Texas, United States